C1orf125 Inhibitors
C1orf125 inhibitors encompass a variety of chemical compounds that interact with specific signaling pathways to reduce the functional activity of C1orf125 without affecting its transcription or translation. These inhibitors are not general activators; instead, they are tailored to diminish the activity of C1orf125 by targeting the pathways it is directly involved in. For instance, kinase inhibitors such as Staurosporine operate by halting phosphorylation events that are essential for the proper signaling functions of C1orf125. Similarly, inhibitors such as LY 294002 and Wortmannin specifically target the PI3K/AKT pathway, resulting in a downstream reduction of C1orf125 activity, which is crucial for cell survival and proliferation signaling. Other inhibitors, like PD 98059 and U0126, precisely inhibit the MAPK/ERK pathway, which is another pathway C1orf125 may be involved in; thus, its activity is indirectly decreased when the pathway is blocked.
Proteasome inhibitors, such as Bortezomib, lead to an indirect reduction of C1orf125 activity by disrupting the degradation of regulatory proteins that could suppress C1orf125 or alter its stability. Cell cycle inhibitors like PD 0332991 also play a role in diminishing the functional activity of C1orf125 by arresting the cell cycle, which could be significant if C1orf125 has a role in cell division. Additionally, Trichostatin A, as an HDAC inhibitor, changes gene expression patterns, which can result in the reduced activity of proteins that share pathways with C1orf125, leading to its functional inhibition. Lastly, Thapsigargin, by disrupting calcium homeostasis, can indirectly diminish C1orf125 activity if it is part of calcium-dependent signaling mechanisms, highlighting the diverse biochemical strategies employed to inhibit C1orf125.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting kinase activity, it can hinder phosphorylation events necessary for C1orf125 function, leading to the diminished functional activity of C1orf125 in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of PI3K. By blocking PI3K, it impedes the PI3K/AKT pathway, which is crucial for the regulation of many proteins, including C1orf125; this results in reduced activity of C1orf125 linked to this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central regulator of cell growth and proliferation. Since C1orf125 is downstream of mTOR signaling, inhibition of mTOR leads to a decrease in C1orf125 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which works upstream of ERK in the MAPK pathway. Blocking MEK leads to reduced ERK activation, indirectly diminishing the activity of C1orf125 that is regulated by the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. It prevents the activation of MAPK pathways involved in inflammation and stress response. As such, it indirectly decreases the functional activity of C1orf125 associated with these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. By inhibiting PI3K, it interferes with downstream signaling pathways, including those involving C1orf125, leading to diminished signaling and functional activity of C1orf125. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, modulating the c-Jun N-terminal kinase pathway. By inhibiting JNK, it indirectly diminishes the activity of C1orf125 if C1orf125 is modulated as part of stress or apoptosis pathways mediated by JNK. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting proteasomal degradation, it can lead to the accumulation of regulatory proteins that may suppress the activity of C1orf125 or affect its stability. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 is a CDK4/6 inhibitor. It arrests the cell cycle, potentially decreasing the activity of C1orf125 if C1orf125 is involved in cell cycle regulation or if its activity peaks at specific cell cycle stages. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDAC). It alters chromatin structure and gene expression, which could lead to the downregulation of proteins involved in the same pathways as C1orf125, thereby diminishing its activity. | ||||||